login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Clinical vs. anatomical risk stratification following complex PCI


Friday, 05 Aug 2011 10:27
Ralf Lehmann
Ralf Lehmann


By Ralf Lehmann


Surgical or interventional coronary revascularisation is the primary therapeutic choice in coronary artery disease patients with multivessel disease or with involvement of the left main coronary artery (LMCA). The decision between revascularisation by percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in multivessel disease patients is often made by estimating the perioperative mortality for CABG using logistic regression-based clinical risk scores such as the EuroSCORE. However, the EuroSCORE is not validated regarding long-term outcome after CABG. The SYNTAX Score represents an anatomical risk stratification score for coronary artery disease patients and has recently been proposed to predict clinical outcome after multivessel PCI. However, the prognostic impact of different clinical and anatomical risk stratification scores for the long-term survival after multivessel PCI has not yet been investigated and compared sufficient. Finally, current guidelines on choosing a revascularisation strategy only focus on anatomical features rather than on clinical parameters.

 

In order to investigate these questions we conducted a single-centre registry with “all-comers” patients. Our study population consisted of 740 consecutive patients undergoing coronary stent implantation in at least two main vessel territories (LAD, RCA, RCX, RIM, LMCA=counted as two territories) in a single session at the University Hospital of Frankfurt, Germany. Clinical long-term follow-up regarding survival was available in a total of 726 (98%) patients with a mean follow-up of 5.3±2.1 years (patients alive).

 

Nearly half of the patients received multivessel PCI in the setting of an acute coronary syndrome (n=150 NSTEMI; n=191 STEMI). The mean age was 65±11 years, 77% were male, and 29% of the patients were diabetic. By definition the EuroSCORE was markedly lower for stable patients in comparison to patients with an acute coronary syndrome (stable 4.1±4.5, NSTEMI 13.9±13.3, STEMI 18.1±18.7, p <0.001). However, for the SYNTAX Score this difference was much less pronounced but still significant (stable coronary artery disease 14.9±8.6; NSTEMI 17.8±9.9; STEMI 18.3±9.0: p <0.001).

The patient population was divided into tertiles for each of the calculated scores.

 

Subsequently Kaplan-Meier survival estimates were performed to compare the different risk levels. Patients in the higher EuroSCORE tertile experienced a dramatically elevated mortality risk across the entire study period when compared with the lower two tertiles. The elevated mortality rate in the highest tertiles of the clinical scores was attributed in part to the high short-term mortality of patients with acute myocardial infarction and especially cardiogenic shock. This led us to perform a separate analysis for stable patients only, in which the discrimination of the long-term survival by tertiles of EuroSCORE was even more pronounced, as reflected by the diverging Kaplan-Meier curves. These results indicate that the discriminating potential of the clinical scores is not only powered by short term “acute” clinical parameters. Finally, the SYNTAX Score predicts long-term survival worse than EuroSCORE, as shown by a smaller difference between the highest and lowest tertiles. In the stable patient population, the SYNTAX Score lost its predictive ability completely.

 

The outstanding role of the EuroSCORE was confirmed by a multivariable Cox regression analysis adjusted for the relevant baseline characteristics. The EuroSCORE remained as independent predictors of long-term mortality in the entire population (HR per tertile 2.03; 95% CI 1.53–2.69).

 

In conclusion, a combination of clinical and anatomical risk factors may provide the optimal predictive model in patients undergoing multivessel PCI. Furthermore, the ideal combination of clinical and anatomic risk stratification should be conclusive for patients undergoing CABG as well.

 

Ralf Lehmann is an interventional cardiologist at Klinikum der JW Goethe Universität, Frankfurt, Germany.  





Add New Comment

Related Items


Most popular


Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

ABSORB II study shows Absorb is comparable to Xience drug-eluting stent
Wednesday, 17 Sep 2014
At one year, overall clinical outcomes for Absorb (Abbott) were comparable to Xience (Abbott), and people treated with Absorb experienced a significantly lower rate of angina. ABSORB II study shows Absorb is comparable to Xience drug-eluting stent

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions